Edwards Lifesciences (EW) Shares Soar 0.42% on FDA Approval

Edwards Lifesciences (EW) shares rose to their highest level since July 2024 today, with an intraday gain of 0.42%.

The strategy of buying EW shares after they reached a recent high and holding for 1 week yielded moderate returns over the past 5 years. The annualized return was 8.33%, slightly underperforming the market by 1.67 percentage points. With a final value of $1,486.47 for a $1,000 investment, the strategy showed that compounded returns, although respectable, can be improved by optimizing the selection of high-growth stocks or adjusting the holding period based on market conditions and stock performance.

Edwards Lifesciences recently received FDA approval for its transcatheter aortic valve replacement (TAVR) on May 1, 2025. This regulatory milestone is expected to have a positive impact on the company's stock price, as it validates the safety and efficacy of their innovative medical device. The approval is likely to boost investor confidence and drive demand for the TAVR system, potentially leading to increased revenue and market share for Edwards Lifesciences.

In addition to the FDA approval, Edwards Lifesciences has also seen positive market sentiment in recent pre-market sessions. This indicates that investors are optimistic about the company's future prospects and are willing to invest in its stock. The combination of regulatory approval and positive market sentiment is likely to continue driving the stock price higher in the coming weeks and months.